Yield of brain18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 47, Issue 10, 2006, Pages 1607-1611

  Posther, Katherine E ^a   McCall, Linda M ^a   Harpole Jr , David H ^a   Reed, Carolyn E ^b   Putnam Jr , Joe B ^c   Rusch, Valerie W ^d   Siegel, Barry A ^e  

^a DUKE CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SODIUM IODIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG UPTAKE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; BRAIN; BRAIN TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

AGED; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; WHOLE BODY IMAGING;

EID: 33947207257     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
2. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9:633-643.
3. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med. 2000;343:254-261.
4. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1392.
5. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943-1951.
6. Jennison C, Turnbull BW. Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics. 1983;25:49-58.
7. Newman SJ, Hanssen HH. Frequency, diagnosis and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492-496.
8. Tarver RD, Richmond BD, Klatte EC. Cerebral metastases from lung carcinoma: neurological and CT correlation. Radiology. 1984;153:689-692.
9. Kormas P, Bradshaw JR, Jeyasingham K. Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma. Thorax. 1992;47:106-108.
10. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest. 2003;123(suppl):147S-156S.
11. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G. Costeffectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995;108:1264-1271.
12. Yokoi K, Miyazawa N, Toshimoto A. Brain metastasis in resected lung cancer: value of intensive follow-up with computed tomography. Ann Thorac Surg. 1996;61:546-551.
13. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999;115:714-719.
14. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 2001;120:521-527.
15. Weder W, Schmid RA, Bruckhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886-893.
16. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomography imaging. Ann Thorac Surg. 1995;60:1573-1581.
17. 18F]FDG PET in the management of metastatic brain tumors. Acta Neurochir (Wien). 1998;140:665-674.
18. 18F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med. 2002;43:1432-1437.
19. Newman SJ, Hansen HH. Frequency, diagnosis and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492-496.
20. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from noncentral nervous system tumors: evaluation with PET. Radiology. 1993;186:37-44.
21. Rohren EM, Provenzale JM, Barboriak DP, et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of noncentral nervous system malignancy. Radiology. 2003;226:181-187.
22. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun. 1996;17:197-198.
23. 18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Mol Imaging Biol. 2002;4:359-362.
24. 18F- fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344:1265-1266.
25. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole body PET. Radiology. 1999;212:803-809.